DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Epalrestat
Epalrestat
IP Vol.2 No.2 Jul-Dec 2014.Pmd
Review of Nisha Amalaki –An Ayurvedic Formulation of Turmeric and Indian Goose Berry in Diabetes
Evaluation of Effect of Nishamalaki on STZ and HFHF Diet Induced Diabetic
Scholars Journal of Medical Case Reports Prolonged Hypoglycemia
Aldose Reductase Inhibitors for Diabetic Cataract: a Study of Disclosure Patterns in Patents and Peer Review Papers
Repurposing of Drugs for Triple Negative Breast Cancer: an Overview
Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
Anatomical Classification Guidelines V2021 EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021
Aldose Reductase Inhibitor Epalrestat Alleviates High Glucose-Induced Cardiomyocyte Apoptosis Via ROS
The Sulfonylurea Drug, Glimepiride, Stimulates Glucose Transport
United States Patent (19) 11 Patent Number: 5,981,594 Okamoto Et Al
Vitamin B12 Supplementation in Diabetic Neuropathy: a 1-Year, Randomized, Double-Blind, Placebo-Controlled Trial
Evaluation of the Aldose Reductase Inhibitor Fidarestat on Ischemia-Reperfusion Injury in Rat Retina
Cognitive and Functional Decline in Patients with Mild Alzheimer Dementia with Or Without Comorbid Diabetes
Stembook 2018.Pdf
Sitagliptin As Incretin-Based Therapy (IBT), Or Combined Epalrestat A
Comparison of Efficacy and Safety of Epalrestat with Methylcobalamin in Patients with Diabetic Neuropathy”
Epalrestat, an Aldose Reductase Inhibitor, Reduces the Levels of Nε-(Carboxymethyl)Lysine Protein Adducts and Their Precursors in Erythrocytes from Diabetic Patients
Top View
Complications Stratified Analyses for Selecting Appropriate Target Patients
The Clinical Efficacy of Epalrestat Combined with Α-Lipoic Acid In
Comparison of Safety and Efficacy of Pregabalin, Duloxetine and Their
Florencio Zaragoza Dörwald Lead Optimization for Medicinal Chemists
Repurposing the Aldose Reductase Inhibitor and Diabetic Neuropathy Drug Epalrestat for the Congenital Disorder of Glycosylation PMM2-CDG Sangeetha Iyer1, Feba S
The Fate of Aldose Reductase Inhibition and Sorbitol Dehydrogenase Activation
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
Product List
Anatomical Classification Guidelines V2018 EPHMRA ANATOMICAL
(12) United States Patent (10) Patent No.: US 9,526,728 B2 Klein Et Al
In-Silico Analysis of Natural Products That Modulates Enzymes of Diabetic Target
Aldose Reductase Inhibitors As Potential Therapeutic Drugs of Diabetic Complications
Pharmacological Modulation of Long Cardiac QT Interval in Ex Vivo and in Vitro Experimental Models
THE ANTISEPTIC - a MONTHLY JOURNAL of MEDICINE & SURGERY Vol 115 No 1 CONTENTS JANUARY 2018 (Pages : 1-52)
A Molecular Modeling Study of Novel Aldose Reductase (AR) Inhibitors
Medicine & Appliance
Effects of Cilostazol Tablets Combined with Epalrestat
(12) Patent Application Publication (10) Pub. No.: US 2017/0014495 A1 Sarangarajan Et Al
(12) Patent Application Publication (10) Pub. No.: US 2016/0082123 A1 RAU Et Al
Buformin/Exenatide 439 Porphyria
Pharmaceutical Chemistry and Analysis Name
022271Orig1s000
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Type 2 Diabetes Current Awareness Bulletin September 2020
Epalrestat Increases Intracellular Glutathione Levels in Schwann Cells Through Transcription Regulation$
List of Ninety Seven Anti-Diabetic Drugs
Anatomical Classification Guidelines V2006A EPHMRA ANATOMICAL
Gujarat Technological University Student List for M.Pharm Sem 3 (Regular) Dissertation Phase-1 Exam (Winter 2019) GTU/W19/DP-1/MPH-3213/12167 Date:- 11/11/2019
Customs Tariff - Schedule
(12) Patent Application Publication (10) Pub. No.: US 2014/0296257 A1 Hersel Et Al
WO 2016/192680 Al 8 December 2016 (08.12.2016) P O P C T
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-Diabetic Diseases
A Study on Cost Analysis in Diabetic Patients with Cardiovascular Complications in a Tertiary Care Teaching Hospital
Enhanced Dissolution and Solubility of Epalrestat with Β-Cyclodextrin
8. JCD Vol 3 No 1 Quiz
All India Institute of Medical Sciences Patna
WO 2012/170676 Al 13 December 2012 (13.12.2012) P O P C T
Appendices a – F December 2014
W.U.S. Health Centre University of Delhi Delhi-110007
Effectiveness of Treatments for Diabetic Peripheral Neuropathy Amendment: May 9, 2016
Active Pharmaceutical Ingredient (API)
Effects of a Novel Potent Aldose Reductase Inhibitor, GP-1447, on Aldose Reductase Activity in Vitro and on Diabetic Neuropathy and Cataract Formation in Rats
Management of Diabetes and Hyperglycemia in Hospitals
Aldose Reductase Inhibition Counteracts Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase Activation in Tissue Sites for Diabetes Complications Irina G